Episurf Medical (Nasdaq: EPIS B) today announces that the company will enter the Polish market. Access to the Polish market will be enabled through co-operation with a local partner, and the local product registration, initially of the Episealer® knee implants, is in its final phase.
“On the back of the strong Episealer® clinical results that are currently being presented throughout Europe, we are focusing our expansion strategy towards activities that create prerequisites for future growth. Enabling access to the Polish market is one such activity. There are an estimated 10,000 – 15,000 knee replacement surgeries performed annually in Poland, and we have assessed the commercial opportunities for us as being attractive. We look forward to helping patients in Poland, who suffer from early knee osteoarthritis, to recover from severe knee pain” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 27 September 2018.